Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Vegums develop multivitamin gummies for a vegan and plant-based lifestyle. The company argues that some vitamins are difficult to get from a plant-only diet, such as vitamin D, B12, and iodine. Vegums has researched and incorporated non-animal vitamin ingredients into its products to address that issue. The company asserts that its products are 100% plastic-free and biodegradable. It claims that the number of vegans in the UK grew by 40% in 2020, and shows no sign of slowing down in 2021. It aims to become a contender in this segment. Vegums won the World Plant Award 2020 for the 'Best Plant-Based Start-Up', has a social media following of over 15,700 on Instagram, achieved 4.8/5 on TrustPilot, and scaled from selling 1 pack of Vegums to over 9,000 a month to its customers. It will use the investment for New Product Development (NPD), team expansion, and launching into new markets and countries.
days to go:
Expired
investment:
£312,463
The Asset Exchange Ltd is an asset-backed lender within the UK used car finance market providing cars and loans to borrowers who are unable to use traditional lending sources for vehicle finance. They use compliant Hire Purchase Agreements which provides customers with high levels of consumer protection.
days to go:
Expired
investment:
£63,064
Husky is the UK’s only open, SaaS platform for workplace pensions. For employers, the platform deals with legal and compliance burdens of auto-enrolment while helping reduce pension costs. For individuals and company directors, the app is instrumental in bringing profitable and responsible investments with the Husky for Everyone app. And for advisers and accountants, it ensures strong client relationships amidst transparency and efficiency. Close to 1.4 million employers & 22.6 million workers are affected by the UK’s automatic enrolment (AE) legislation. Within this market, a conservative estimate of fees charged on employees by pension providers is £2 billion a year; Husky aims to disrupt this market & is ready to scale. Its method of operation has led to it achieving important milestones. With more than 1000 firms onboarded, a 92% renewal rate, and an average annual fee of £438, Husky charges its onboarded firms (including Crowdcube) with monthly recurring fees laid out as part of a 3-year subscription model. With the funds received, the company aims to disrupt the relatively stagnant workplace pensions industry with innovative products and empower its customers.
days to go:
Expired
investment:
£417,338
Billon have created a technology that enables zero cost global payments by the use of a simple mobile app. Billon's mobile app allows you to instantly pay for the rest of an article from the Guardian or even donate to your favourite Youtubers with a few clicks of a button.
days to go:
Expired
investment:
£1,406,667
Felcana is a patented Eco-system of connected devices: Helix, Home Hub, Micro-Location Beacons and the Felcana application which work together to monitor the pet's (cat or dogs) well-being. This Digital Pet Health Platform tracks pet's behaviour and provides the vet, rich data leading to faster diagnosis and faster treatment. Felcana has been developed by a world-class team of vets and engineers and, it has been designed and tested by using the latest materials, designs, and techniques. Felcana has won the Design Spark Award in 2017. It is making unique partnerships with leading pet industries and the UK's largest pet health plan provider, the world's top-ranked vet school and The Royal Veterinary College. The new investment will enable it to grow consumer reach and accelerate its sales.
days to go:
Expired
investment:
£343,926
Chip is one of the fastest-growing Fintech companies in the UK. Chip has built an app that uses the user's banking app to make personalised decisions about their money. Its user base has doubled since its previous fundraising in 2018. The company has 153,000 accounts, and it has processed more than £130m of savings. ChipX is the company's revolutionary returns platform and it has a waiting list of more than 50,000 people. The company is a winner of the British Bank Award, 2 Crowdcube awards, and 1 World Banking Award. It has welcomed many management executives from Funding Circle, Monzo, and Purple Bricks. Chip is now scaling with market-leading returns on ChipX. It aims to build the biggest savings account in the world. With the proceeds, the company will double its team and expand ChipX in the €10 trillion European savings market.
days to go:
Expired
investment:
£3,768,260
